trying...
29108833 2018 03 13 2023 01 20 1347-8648 135 3 2017 Nov Journal of pharmacological sciences J Pharmacol Sci Arctiin protects against cardiac hypertrophy through inhibiting MAPKs and AKT signaling pathways. 97 104 97-104 10.1016/j.jphs.2017.05.012 S1347-8613(17)30103-2 The mitogen-activated protein kinases (MAPKs) and protein kinase B (AKT) pathways have emerged as essential intracellular signaling pathways in eukaryotic cells, particularly as regulators of cardiac hypertrophy. Previous studies indicated that arctiin, an active ingredient of biennial dried ripe burdock, could exhibit potent anti-inflammatory and anti-allergic activities via down-regulating the activation of MAPKs and AKT pathways. However, little is known about its effects on cardiac hypertrophy. Therefore, the present study aimed to explore whether arctiin could attenuate cardiac hypertrophy. Arctiin (80 mg/kg) was administered by oral gavage once daily for 3 weeks from 1 week after surgery. Then, the mice were subjected to either chronic pressure overload generated by aortic banding (AB) or sham surgery (control group). Cardiac function was assessed by echocardiography. The results indicated that arctiin attenuated cardiac hypertrophy induced by AB, and suppressed cardiac fibrosis and accumulation of collagen in vivo. Arctiin also inhibit the activation of MAPKs and AKT occurs in response to hypertrophic stimuli. Arctiin attenuated phenylephrine-induced hypertrophy of myocytes in vitro. In conclusion, arctiin can improve cardiac function and prevent the development of cardiac hypertrophy by blocking the MAPKs and AKT signaling pathways. Copyright © 2017 The Authors. Production and hosting by Elsevier B.V. All rights reserved. Li Jing J Department of Cardiology, Renmin Hospital of Wuhan University, Wuhan, China; Cardiovascular Research Institute of Wuhan University, Wuhan, China. Yuan Yu-Pei YP Department of Cardiology, Renmin Hospital of Wuhan University, Wuhan, China; Cardiovascular Research Institute of Wuhan University, Wuhan, China. Xu Si-Chi SC Department of Cardiology, Renmin Hospital of Wuhan University, Wuhan, China; Cardiovascular Research Institute of Wuhan University, Wuhan, China. Zhang Ning N Department of Cardiology, Renmin Hospital of Wuhan University, Wuhan, China; Cardiovascular Research Institute of Wuhan University, Wuhan, China. Xu Chun-Ru CR Department of Cardiology, Renmin Hospital of Wuhan University, Wuhan, China; Cardiovascular Research Institute of Wuhan University, Wuhan, China. Wan Chun-Xia CX Department of Cardiology, Renmin Hospital of Wuhan University, Wuhan, China; Cardiovascular Research Institute of Wuhan University, Wuhan, China. Ren Jie J Department of Cardiology, Renmin Hospital of Wuhan University, Wuhan, China; Cardiovascular Research Institute of Wuhan University, Wuhan, China. Zeng Xiao-Feng XF Department of Cardiology, Renmin Hospital of Wuhan University, Wuhan, China; Cardiovascular Research Institute of Wuhan University, Wuhan, China. Tang Qi-Zhu QZ Department of Cardiology, Renmin Hospital of Wuhan University, Wuhan, China; Cardiovascular Research Institute of Wuhan University, Wuhan, China. Electronic address: qztang@whu.edu.cn. eng Journal Article 2017 08 10 Japan J Pharmacol Sci 101167001 1347-8613 0 Furans 0 Glucosides EC 2.7.11.1 Proto-Oncogene Proteins c-akt TM5RQ949K7 arctiin IM Administration, Oral Animals Arctium chemistry Cardiomegaly drug therapy etiology pathology Cells, Cultured Disease Models, Animal Fibrosis Furans administration & dosage pharmacology therapeutic use Glucosides administration & dosage pharmacology therapeutic use MAP Kinase Signaling System drug effects Male Mice, Inbred C57BL Myocytes, Cardiac pathology Phytotherapy Proto-Oncogene Proteins c-akt metabolism Signal Transduction drug effects AKT Arctiin Cardiac fibrosis Cardiac hypertrophy MAPKs 2016 8 23 2017 5 11 2017 5 15 2017 11 8 6 0 2018 3 14 6 0 2017 11 8 6 0 ppublish 29108833 10.1016/j.jphs.2017.05.012 S1347-8613(17)30103-2 trying2... trying...
83114 5 0 1 MCID_676f085caf19616c980414f9
39728934
39726054
39725339
39724625
39724446
cardiac hypertrophy "cardiomegaly"[MeSH Terms] OR "cardiomegaly"[All Fields] OR ("cardiac"[All Fields] AND "hypertrophy"[All Fields]) OR "cardiac hypertrophy"[All Fields] "cardiomegaly"[MeSH Terms] OR "cardiomegaly"[All Fields] OR ("cardiac"[All Fields] AND "hypertrophy"[All Fields]) OR "cardiac hypertrophy"[All Fields]
trying2... trying... trying2...
Arctiin protects against cardiac hypertrophy through inhibiting MAPKs and AKT signaling pathways. | LitMetric
Purpose : The mitogen-activated protein kinases (MAPKs) and protein kinase B (AKT) pathways have emerged as essential intracellular signaling pathways in eukaryotic cells, particularly as regulators of cardiac hypertrophy. Previous studies indicated that arctiin, an active ingredient of biennial dried ripe burdock, could exhibit potent anti-inflammatory and anti-allergic activities via down-regulating the activation of MAPKs and AKT pathways. However, little is known about its effects on cardiac hypertrophy. Therefore, the present study aimed to explore whether arctiin could attenuate cardiac hypertrophy.General Methods : Arctiin (80 mg/kg) was administered by oral gavage once daily for 3 weeks from 1 week after surgery. Then, the mice were subjected to either chronic pressure overload generated by aortic banding (AB) or sham surgery (control group). Cardiac function was assessed by echocardiography.Findings : The results indicated that arctiin attenuated cardiac hypertrophy induced by AB, and suppressed cardiac fibrosis and accumulation of collagen in vivo. Arctiin also inhibit the activation of MAPKs and AKT occurs in response to hypertrophic stimuli. Arctiin attenuated phenylephrine-induced hypertrophy of myocytes in vitro.Conclusions : In conclusion, arctiin can improve cardiac function and prevent the development of cardiac hypertrophy by blocking the MAPKs and AKT signaling pathways.
Similar Publications
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!